Staphylococcus aureus Investigational Vaccine Elicits a Positive Immune Response in Phase 1 Study
May 09 2011 - 7:00AM
Business Wire
Inhibitex, Inc. (Nasdaq: INHX), announced today that Pfizer Inc.
presented safety and immunogenicity data from a Phase 1
double-blind randomized placebo controlled study in 408 healthy
volunteers of a novel three antigen Staphylococcus aureus
investigational vaccine (SA3Ag) at the 21st European Congress of
Clinical Microbiology and Infectious Diseases (ECCMID) and 27th
International Congress of Chemotherapy (ICC) in Milan, Italy
(ECCMID/ICC). The vaccine candidate is comprised of S. aureus
capsular polysaccharide serotypes 5 and 8 conjugated to CRM197 and
the recombinant surface-expressed MSCRAMM protein, clumping factor
A. In the Phase 1 study, the vaccine elicited a positive immune
response to each of the three components. Pfizer has worldwide
exclusive rights to the Company’s MSCRAMM protein platform for the
development of staphylococcal vaccines.
“We are very encouraged with the initial safety and
immunogenicity profile of SA3Ag in this Phase 1 trial,” stated Dr.
Joseph Patti, Senior Vice President and Chief Scientific Officer of
Inhibitex, Inc. “We are pleased with the clinical progress of the
staph vaccine program by our partner Pfizer and look forward to its
continued development.”
About Staphylococcus aureus Infections
S. aureus is a leading cause of hospital-acquired infections in
the United States. Hospital-acquired S. aureus, and in particular,
methicillin-resistant S. aureus (MRSA), infections are generally
associated with a longer hospital stay, greater morbidity and
mortality and high treatment costs. The emergence of hard-to-treat
MRSA, in both the hospital and the community setting, and the
additional costs to treat these infections provide a rationale for
the development of a vaccine to prevent S. aureus infections.
About Inhibitex
Inhibitex, Inc., headquartered in Alpharetta, Georgia, is a
biopharmaceutical company focused on developing products to prevent
and treat serious infectious diseases. The Company’s pipeline
includes FV-100, which is in Phase 2 clinical development for the
treatment of shingles, and INX-189, a nucleotide polymerase
inhibitor in clinical development for the treatment of chronic
hepatitis C infections. The Company also has additional HCV
nucleotide polymerase inhibitors in preclinical development and has
licensed the use of its proprietary MSCRAMM® protein platform to
Pfizer for the development of staphylococcal vaccines. For
additional information about the Company, please visit
www.inhibitex.com.
Inhibitex® and MSCRAMM® are registered trademarks of Inhibitex,
Inc.
Inhibitex, Inc. (MM) (NASDAQ:INHX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Inhibitex, Inc. (MM) (NASDAQ:INHX)
Historical Stock Chart
From Jul 2023 to Jul 2024